|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/29/17 Cell MedX Corp. 10-K 5/31/17 90:3M Empire Stock Transf… Inc |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 490K
2: EX-10.49 Loan Agreement and Note Payable Dated January 11, HTML 33K
2017
3: EX-10.50 Loan Agreement and Note Payable Dated January 13, HTML 33K
2017
4: EX-10.51 Loan Agreement and Note Payable Dated February 14, HTML 33K
2017
5: EX-10.52 Loan Agreement and Note Payable Dated March 8, HTML 33K
2017
6: EX-10.53 Loan Agreement and Note Payable Dated April 18, HTML 33K
2017
7: EX-10.54 Loan Agreement and Note Payable Dated May 5, 2017 HTML 33K
8: EX-21.1 List of Subsidiaries HTML 26K
9: EX-31.1 Certification -- §302 - SOA'02 HTML 31K
10: EX-31.2 Certification -- §302 - SOA'02 HTML 31K
11: EX-32.1 Certification -- §906 - SOA'02 HTML 28K
12: EX-32.2 Certification -- §906 - SOA'02 HTML 27K
19: R1 Document and Entity Information HTML 56K
20: R2 Consolidated Balance Sheets HTML 84K
21: R3 Balance Sheets (Parenthetical) HTML 36K
22: R4 Consolidated Statements of Operations HTML 77K
23: R5 Consolidated Statements of Stockholders' Equity HTML 75K
(Deficit)
24: R6 Consolidated Statements of Stockholders' Equity HTML 31K
(Parenthetical)
25: R7 Consolidated Statements of Cash Flows HTML 105K
26: R8 Organization and Nature of Operations HTML 34K
27: R9 Summary of Significant Accounting Policies HTML 49K
28: R10 Related Party Transactions, Disclosure HTML 60K
29: R11 Equipment, Disclosure HTML 37K
30: R12 Inventory Disclosure HTML 30K
31: R13 Unearned Revenue Disclosure HTML 29K
32: R14 Notes and Advances Payable, Disclosure HTML 67K
33: R15 Divestiture of Avyonce, Disclosure HTML 31K
34: R16 Share Capital, Disclosure HTML 89K
35: R17 Income Taxes, Disclosure HTML 52K
36: R18 Subsequent Events Disclosure HTML 34K
37: R19 Organization and Nature of Operations: Going HTML 31K
Concern (Policies)
38: R20 Summary of Significant Accounting Policies: Basis HTML 29K
of Presentation (Policies)
39: R21 Summary of Significant Accounting Policies: HTML 31K
Principles of Consolidation, Policy (Policies)
40: R22 Summary of Significant Accounting Policies: HTML 29K
Reclassifications, Policy (Policies)
41: R23 Summary of Significant Accounting Policies: HTML 31K
Accounting Estimates, Policy (Policies)
42: R24 Summary of Significant Accounting Policies: HTML 32K
Foreign Currency Translations and Transactions,
Policy (Policies)
43: R25 Summary of Significant Accounting Policies: HTML 32K
Revenue Recognition, Policy (Policies)
44: R26 Summary of Significant Accounting Policies: HTML 31K
Inventory Valuation, Policy (Policies)
45: R27 Summary of Significant Accounting Policies: HTML 31K
Research and Development Costs, Policy (Policies)
46: R28 Summary of Significant Accounting Policies: Income HTML 33K
Taxes, Policy (Policies)
47: R29 Summary of Significant Accounting Policies: Loss HTML 31K
Per Share, Policy (Policies)
48: R30 Summary of Significant Accounting Policies: HTML 31K
Long-lived Assets, Policy (Policies)
49: R31 Summary of Significant Accounting Policies: HTML 30K
Equipment, Policy (Policies)
50: R32 Summary of Significant Accounting Policies: Fair HTML 32K
Value Measurements, Policy (Policies)
51: R33 Summary of Significant Accounting Policies: Stock HTML 32K
Options and Other Stock-based Compensation, Policy
(Policies)
52: R34 Summary of Significant Accounting Policies: Recent HTML 32K
Accounting Pronouncements (Policies)
53: R35 Related Party Transactions, Disclosure: Schedule HTML 39K
of Amounts Due to Related Parties (Tables)
54: R36 Related Party Transactions, Disclosure: Schedule HTML 47K
of Transactions with Related Parties (Tables)
55: R37 Equipment, Disclosure: Amortization Schedule for HTML 36K
Equipment (Tables)
56: R38 Notes and Advances Payable, Disclosure: Schedule HTML 54K
of Short-term Loans and Advances Outstanding
(Tables)
57: R39 Notes and Advances Payable, Disclosure: Fair HTML 32K
values assumptions of the warrants - Term Loan
Agreement (Tables)
58: R40 Share Capital, Disclosure: Black-Scholes Option HTML 31K
pricing valuation - Stock Options granted to
Technology Vendors (Tables)
59: R41 Share Capital, Disclosure: Black-Scholes Option HTML 32K
pricing valuation - Stock Options granted to Chief
Medical Officer (Tables)
60: R42 Share Capital, Disclosure: Black-Scholes Option HTML 32K
pricing valuation - Stock Options granted to CEO,
President and a member of the board (Tables)
61: R43 Share Capital, Disclosure: Schedule of Stock HTML 44K
Option Activity (Tables)
62: R44 Share Capital, Disclosure: Schedule of Stock HTML 36K
Options Outstanding (Tables)
63: R45 Share Capital, Disclosure: Exercise price of HTML 33K
warrants issued for Term Loan Agreement (Tables)
64: R46 Share Capital, Disclosure: Exercise price of HTML 32K
warrants issued during stock offering 2016
(Tables)
65: R47 Share Capital, Disclosure: Schedule of Warrant HTML 34K
Activity (Tables)
66: R48 Share Capital, Disclosure: Schedule of Warrant HTML 35K
Details (Tables)
67: R49 Income Taxes, Disclosure: Schedule of Effective HTML 41K
Income Tax Rate Reconciliation (Tables)
68: R50 Income Taxes, Disclosure: Schedule of Deferred Tax HTML 38K
Assets and Liabilities (Tables)
69: R51 Organization and Nature of Operations: Going HTML 30K
Concern (Details)
70: R52 Related Party Transactions, Disclosure: Schedule HTML 40K
of Amounts Due to Related Parties (Details)
71: R53 Related Party Transactions, Disclosure: Schedule HTML 52K
of Transactions with Related Parties (Details)
72: R54 Equipment, Disclosure (Details) HTML 29K
73: R55 Equipment, Disclosure: Amortization Schedule for HTML 36K
Equipment (Details)
74: R56 Inventory Disclosure (Details) HTML 30K
75: R57 Unearned Revenue Disclosure (Details) HTML 29K
76: R58 Notes and Advances Payable, Disclosure: Schedule HTML 49K
of Short-term Loans and Advances Outstanding
(Details)
77: R59 Notes and Advances Payable, Disclosure (Details) HTML 52K
78: R60 Divestiture of Avyonce, Disclosure (Details) HTML 31K
79: R61 Share Capital, Disclosure (Details) HTML 52K
80: R62 Share Capital, Disclosure: Schedule of Stock HTML 38K
Option Activity (Details)
81: R63 Share Capital, Disclosure: Schedule of Stock HTML 38K
Options Outstanding (Details)
82: R64 Share Capital, Disclosure: Schedule of Warrant HTML 31K
Activity (Details)
83: R65 Share Capital, Disclosure: Schedule of Warrant HTML 30K
Details (Details)
84: R66 Income Taxes, Disclosure: Schedule of Effective HTML 45K
Income Tax Rate Reconciliation (Details)
85: R67 Income Taxes, Disclosure: Schedule of Deferred Tax HTML 34K
Assets and Liabilities (Details)
86: R68 Income Taxes, Disclosure (Details) HTML 32K
87: R69 Subsequent Events Disclosure (Details) HTML 39K
89: XML IDEA XML File -- Filing Summary XML 163K
88: EXCEL IDEA Workbook of Financial Reports XLSX 67K
13: EX-101.INS XBRL Instance -- cmxc-20170531 XML 684K
15: EX-101.CAL XBRL Calculations -- cmxc-20170531_cal XML 54K
16: EX-101.DEF XBRL Definitions -- cmxc-20170531_def XML 263K
17: EX-101.LAB XBRL Labels -- cmxc-20170531_lab XML 482K
18: EX-101.PRE XBRL Presentations -- cmxc-20170531_pre XML 474K
14: EX-101.SCH XBRL Schema -- cmxc-20170531 XSD 147K
90: ZIP XBRL Zipped Folder -- 0001393905-17-000266-xbrl Zip 71K
| ex-10.52 |
EXHIBIT 10.52
LOAN AGREEMENT
Tradex Capital Corp. (the “Lender”) of 1177 W. Hastings Street, Suite 1920, Vancouver, BC V6E 2K3, advanced CAD$30,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on March 8, 2017.
The Borrower agrees to repay the Principal Sum on demand, together with interest calculated and compounded monthly at the rate of 6% per year (the “Interest”) from March 8, 2017. The Borrower is liable for repayment for the Principal Sum and accrued Interest and any costs that the Lender incurs in trying to collect the Principal Sum and the Interest.
The Borrower will evidence the debt and its repayment of the Principal Sum and the Interest with a promissory note in the attached form.
| LENDER |
| BORROWER |
| Tradex Capital Corp. |
| Cell MedX Corp. |
|
|
|
|
| Per: |
| Per: |
|
|
|
|
|
|
|
|
| /s/ William Friesen |
| /s/ Yanika Silina |
|
| Yanika Silina, CFO |
PROMISSORY NOTE
| Principal Amount: CAD$30,000 |
FOR VALUE RECEIVED Cell MedX Corp., (the “Borrower”) promises to pay on demand to the order of Tradex Capital Corp. (the “Lender”) the sum of $30,000 lawful money of Canada (the “Principal Sum”) together with interest on the Principal Sum from March 8, 2017 (“Effective Date”) both before and after maturity, default and judgment at the Interest Rate as defined below.
For the purposes of this promissory note, Interest Rate means 6 per cent per year. Interest at the Interest Rate must be calculated and compounded monthly not in advance from and including the Effective Date (for an effective rate of 6.2% per annum calculated monthly), and is payable together with the Principal Sum when the Principal Sum is repaid.
The Borrower may repay the Principal Sum and the Interest in whole or in part at any time.
The Borrower waives presentment, protest, notice of protest and notice of dishonour of this promissory note.
BORROWER
Cell MedX Corp.
Per:
/s/ Yanika Silina
Yanika Silina, CFO
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/29/17 | |||
| For Period end: | 5/31/17 | |||
| 3/8/17 | 4 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 10/15/20 Cell MedX Corp. 10-Q 8/31/20 51:1.9M Empire Stock Transf… Inc 9/15/20 Cell MedX Corp. 10-K 5/31/20 84:2.9M Empire Stock Transf… Inc |